Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
123estimated
Sites
18
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-31 | actual | When the study began enrolling |
| Primary completion | 2024-10-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- Drug: APG-2575
- Drug: Rituximab
- Drug: Ibrutinib
Primary outcomes
what the primary-completion date above is the date OFAdverse events of APG-2575 single agent
measured Up to 6 cycles (each cycle is 28 days).
Objective Response Rate (ORR) of APG-2575 single agent
measured Up to 6 cycles (each cycle is 28 days).
Dose Limiting Toxicities (DLT) of combination therapy
measured 28 days.
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)
measured 28 days.
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed